Clinical and prognostic significance of expression of phosphoglycerate mutase family member 5 and Parkin in advanced colorectal cancer

doi:10.12998/wjcc.v10.i14.4368

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 14

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5816)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

237

WORD

HTML

2525

Figures (1-4)

605

Tables (1-3)

564

Sum=3973

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

272

Download

1556

Sum=1828

May 16, 2022 (publication date) through Feb 23, 2026

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Clinical and Translational Research

World J Clin Cases. May 16, 2022; 10(14): 4368-4379
Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4368

Clinical and prognostic significance of expression of phosphoglycerate mutase family member 5 and Parkin in advanced colorectal cancer

Can Wu, Ming-Liang Feng, Tai-Wei Jiao, Ming-Jun Sun

Can Wu, Ming-Liang Feng, Tai-Wei Jiao, Ming-Jun Sun, Department of Endoscope, The First Hospital Affiliated to China Medical University, Shenyang 110001, Liaoning Province, China

Author contributions: Wu C and Sun MJ designed the research study; Feng ML and Jiao TW performed the research; Wu C and Feng ML contributed new reagents and analytic tools; Wu C and Jiao TW analyzed the data and wrote the manuscript; Wu C has received research funding; and all authors have read and approved the final manuscript.

Supported by the Natural Science Foundation of Liaoning Province, No. 2019-BS-279.

Institutional review board statement: This study was approved by the Institutional Review Board of The First Affiliated Hospital of China Medical University (No. 2021-68-2).

Clinical trial registration statement: This study is registered at clinical hospital center “The First Hospital Affiliated to China Medical University” trial registry. The registration identification number is No. 2021-68-2.

Informed consent statement: Informed consent statement was waived.

Conflict-of-interest statement: There are no conflict of interest.

Data sharing statement: No additional data are available.

Corresponding author: Ming-Jun Sun, Doctor, PhD, Chief Physician, Professor, Department of Endoscope, The First Hospital Affiliated to China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning Province, China. sunydyy@163.com

Received: August 2, 2021
Peer-review started: August 2, 2021
First decision: September 4, 2021
Revised: September 17, 2021
Accepted: March 25, 2022
Article in press: March 25, 2022
Published online: May 16, 2022
Processing time: 283 Days and 16.6 Hours

ARTICLE HIGHLIGHTS

Research background

Phosphoglycerate mutase family member 5 (PGAM5) activates serine/threonine PTEN-induced putative kinase 1/Parkin pathway-mediated mitophagy. However, there are few studies on the clinical and prognostic significance of expression of PGAM5 protein and mitophagy-related protein Parkin in colorectal cancer (CRC) patients.

Research motivation

Both PGAM5 and Parkin protein expression has diagnostic significance for CRC and may become new biomarkers.

Research objectives

To assess the clinical significance of PGAM5 and Parkin proteins, as biomarkers for diagnosis and prognosis of CRC, by studying their expression in advanced CRC tissues and their association with clinicopathological parameters.

Research methods

We used immunohistochemistry to determine the expression of PGAM5 and Parkin in CRC tissues from 100 patients. More than that, we employed western blot to measure PGAM5 and Parkin protein expression in six matched pairs of CRC and adjacent non-tumor tissues.

Research results

We found that both PGAM5 and Parkin protein expression in tumor tissues was significantly higher than that in the adjacent tissues according to immunohistochemical and western blot. What’s more, PGAM5 and Parkin protein levels were significantly positively correlated in advanced CRC tissues. And reduced Parkin protein expression was an independent prognostic factor for overall survival and progression-free survival in CRC patients as evinced by multivariate analysis.

Research conclusions

The expressions of PGAM5 protein and mitophagy-related protein Parkin has diagnostic significance for CRC and may become new biomarkers. Parkin may be a potential marker for the survival of CRC patients.

Research perspectives

Our data provide a promising foundation for increasing the accuracy of clinical judgment and improving the continued development of cancer treatment and personalized treatment strategies for CRC.